University of Texas Southwestern Medical Center
utsouthwestern.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
991
Active
236
Phase 3
43
Total enrollment
915,318
Pipeline matrix
Showing 40 of 112 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Potassium citrate | — | — | — | — | 2 | ||
| Ergocalciferol | — | — | — | — | — | 2 | |
| Calcium Citrate with Vitamin D2 | — | — | — | — | — | 1 | |
| Denosumab | — | — | — | — | — | 1 | |
| Cladribine | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Tafamidis 61 MG | — | — | — | — | — | 1 | |
| Deucravacitinib | — | — | — | — | — | 1 | |
| clozapine | — | — | — | — | — | 1 | |
| risperidone | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | 3 | |||
| EffCaMgCit | — | — | — | — | — | 3 | |
| Admixture of propofol and etomidate at a ratio by volume of 75%/25% | — | — | — | — | — | 1 | |
| Admixture of propofol and etomidate at a ratio by volume of 25%/75% | — | — | — | — | — | 1 | |
| Curcumin | — | — | — | — | — | 1 | |
| Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor | — | — | — | — | — | 1 | |
| Weight loss | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 4 | |
| Ketamine Hydrochloride | — | — | 5 | ||||
| Nivolumab | — | — | — | — | — | 5 | |
| Polypill | — | — | — | — | — | 4 | |
| Ipilimumab | — | — | — | — | — | 3 | |
| Atezolizumab | — | — | — | — | — | 2 | |
| Tirzepatide | — | — | — | — | — | 2 | |
| Cadonilimab | — | — | — | — | 2 | ||
| Lenvatinib | — | — | — | — | — | 2 | |
| Pregnenolone | — | — | — | — | 4 | ||
| Escitalopram | — | — | — | 4 | |||
| Temozolomide | — | — | — | — | 2 | ||
| Midazolam Hydrochloride | — | — | — | — | 2 | ||
| paclitaxel | — | — | — | — | — | 4 | |
| Orlistat | — | — | — | — | — | 3 | |
| Bevacizumab | — | — | — | — | 3 | ||
| Letrozole | — | — | — | — | — | 2 | |
| Abemaciclib | — | — | — | — | 2 | ||
| Low-dose Colchicine at 0.5mg daily | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Afatinib + Prednisone | — | — | — | — | — | 1 | |
| microbubble CEUS Contrast Enhanced Ultrasound | — | — | — | — | — | 1 |
72 more active programs hidden
Next readouts
- 2024-11-08
- 2026-02
- 2026-03-31
- 2026-06
- 2026-06-30
- 2026-07
- 2026-07-01
- 2026-07-31
- 2026-07-31
- 2026-08-18
Top conditions
- Hypertension26
- Depression25
- Breast Cancer22
- Obesity20
- Bipolar Disorder17
- Major Depressive Disorder16
- Prostate Cancer14
- Diabetes13
Frequently asked questions about University of Texas Southwestern Medical Center
- How many clinical trials does University of Texas Southwestern Medical Center have on ClinicalTrials.gov?
- University of Texas Southwestern Medical Center is listed as the lead sponsor on 991 clinical trials in ClinicalTrials.gov, 236 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Texas Southwestern Medical Center's trials are in Phase 3?
- 43 of University of Texas Southwestern Medical Center's trials are in Phase 3, spread across 112 active drug programs.
- What therapeutic areas does University of Texas Southwestern Medical Center focus on?
- University of Texas Southwestern Medical Center's most-studied conditions on ClinicalTrials.gov are Hypertension, Depression, Breast Cancer, Obesity, Bipolar Disorder.
- When are University of Texas Southwestern Medical Center's next clinical trial readouts?
- University of Texas Southwestern Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]”, expected around 2024-11-08.